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Background. The role of inﬂammatory and angiogenic cytokines in patients with inﬂammatory pericardial eﬀusion still remains
uncertain. Methods. We assessed pericardial and serum levels of VEGF, bFGF, IL-1β and TNF-α by ELISA in patients with
inﬂammatory pericardial eﬀusion (PE) of autoreactive (n = 22) and viral (n = 11) origin, and for control in pericardial ﬂuid
(PF) and serum (n = 26) of patients with coronary artery disease (CAD) undergoing coronary artery bypass graft surgery. Results.
VEGF levels were signiﬁcantly higher in patients with autoreactive and viral PE than in patients with CAD in both PE (P = 0,006
for autoreactive and P<0,001 for viral PE) and serum (P<0,001 for autoreactive and P<0,001 for viral PE). Pericardial
bFGF levels were higher compared to serum levels in patients with inﬂammatory PE and patients with CAD (P ≤ 0,001 for CAD;
P ≤ 0,001 for autoreactive PE; P = 0,005 for viral PE). Pericardial VEGF levels correlated positively with markers of pericardial
inﬂammation, whereas pericardial bFGF levels showed a negative correlation. IL-1β and TNF-α were detectable only in few PE
and serum samples. Conclusions. VEGF and bFGF levels in pericardial eﬀusion are elevated in patients with inﬂammatory PE. It is
thus possible that VEGF and bFGF participate in the pathogenesis of inﬂammatory pericardial disease.
1.Introduction
The management of pericardial eﬀusion is an important
clinical problem that remains challenging. However, the
pathogenesis of pericardial ﬂuid accumulation in diﬀer-
ent forms of pericardial disease is still not completely
understood. Inﬂammatory reactions are a major cause of
pericardial eﬀusion. Studies on inﬂammatory pericardial
eﬀusions may elucidate the mechanisms of pericardial ﬂuid
formation and also the general mechanisms of pericardial
inﬂammation. Cytokines are essential mediators of nor-
mal and pathologic immune and inﬂammatory responses.
Particularly, inﬂammatory and angiogenic cytokines are
involved in the pathogenesis of cardiovascular diseases,
including atherosclerosis, myocardial infarction, myocardi-
tis, and cardiomyopathy [1–3]. However, very few data
exist on the activation pattern and pathophysiological role
of inﬂammatory and angiogenic cytokines in pericardial
diseases [4–6]. There are numerous studies on cytokines in
pleural eﬀusion [7–12] in contrast to the limited experience
on pericardial cytokines in pericardial eﬀusion. Cytokines,
such as vascular endothelial growth factor (VEGF), basic
ﬁbroblast growth factor (bFGF), and interleukin-1β (IL-
1β)a n dt u m o rn e c r o s i sf a c t o r - α (TNF-α) are candidates
for the induction of pericardial eﬀusions because they
have been implicated in the induction and ampliﬁcation of
inﬂammatory reactions in exudative eﬀusions [7, 9, 10, 13–
17]. Therefore we measured the concentrations of VEGF,
bFGF, IL-1β,a n dT N F - α in pericardial ﬂuid and serum
from patients with inﬂammatory, nonmalignant pericardial
eﬀusion and patients without pericardial disease.
2.MaterialsandMethods
2.1. Study Population. The study population included 33
consecutive patients with inﬂammatory pericardial eﬀusion
(PE) who underwent subxiphoid, ﬂuoroscopically guided
pericardiocentesis, pericardioscopy, and peri-/epicardial2 Mediators of Inﬂammation
biopsyfortherapeuticand/ordiagnosticreasonsafterwritten
informed consent [18]. For comparison, pericardial ﬂuid
(PF) from 26 patients was obtained and served during open-
heart surgery for coronary artery disease together with a
blood sample for each patient. None of the patients of the
control group had a history of pericardial disease or evidence
of pericardial eﬀusion in echocardiography. The study was
approved by the local ethics committee.
The etiologic diagnosis of inﬂammatory PE followed
the criteria deﬁned by the task force on pericardial diseases
of the European Society of Cardiology [19]. In brief, the
diagnosis of autoreactive inﬂammatory PE was based on
the following criteria [19, 20]: (1) increased number of
lymphocytes/mononuclear cells > 5000/mm3 or the presence
of antimyocardial antibodies in pericardial ﬂuid; (2) inﬂam-
mationinepicardialbiopsiesby≥14cells/mm2;(3)ex clusion
of active viral infection in PE and epicardial biopsies
(no virus isolation, negative PCR for major cardiotropic
viruses, no IgM-titer against cardiotropic viruses in the
PE); (4) exclusion of tuberculosis, Borrelia burgdorferi,
Chlamydia pneumonia, and other bacterial infections by
polymerase chain reaction (PCR) and/or cultures; (5) absent
neoplastic inﬁltration in pericardial ﬂuid and biopsy spec-
imens; (6) exclusion of systemic, metabolic disorders and
uremia. Viral inﬂammatory pericarditis was diagnosed by
the presence of viral genome (parvovirus B19, inﬂuenza A/B,
cytomegalovirus, enterovirus, adenovirus, herpes simplex
virus, and Epstein Barr virus) detected by PCR in peri-
cardial ﬂuid and/or peri-/epicardial biopsies. For extraction
of DNA/RNA from PE and peri-/epicardial biopsies, the
QIAamp Blood Mini Kit and the QIAamp Tissue Kit
(Qiagen, Hilden, Germany) were used. Conditions for PCR
and primers have been described elsewhere [20].
2.2. Sampling of Pericardial Eﬀusion, Pericardial Fluid, and
Peri-/Epicardial Biopsies and Serum. In patients with inﬂam-
matory PE, pericardial eﬀusion samples were obtained
with pericardiocentesis. Pericardial ﬂuid from patients with
coronary artery disease (CAD) was obtained immediately
after incision of the pericardium during coronary artery
bypass graft surgery. Pericardiocentesis was performed in
the cardiac catheterization laboratory using the subxiphoid
route under local anaesthesia, with electrocardiographic and
haemodynamic monitoring. After aspiration of pericardial
ﬂuid, a 0.038
   J-tip guidewire was introduced and its posi-
tion checked in the lateral 90 degrees, the posterior-anterior,
and the right anterior oblique views. The guide wire was
ﬁnally exchanged for a 7 French pigtail catheter. Pericardial
ﬂuid was removed by manual suction. Pericardioscopy was
performed in the same session as pericardiocentesis. After
the evacuation of the pericardial eﬀusion, the pericardial
catheter was exchanged for a 16 French introductory sheath.
A ﬂexible endoscope (Karl Storz AF 1101 Bl) was introduced
in the pericardial space and up to eight peri-/epicardial
biopsies were taken under direct eye control through the
working channel of the instrument.
PE samples were divided for laboratory analysis includ-
ing basic biochemical and cell count parameters, cytology,
bacterial cultures, and polymerase chain reaction (PCR)
for identiﬁcation of cardiotropic viruses (inﬂuenza virus
A/B, Parvovirus B19, cytomegalovirus, enterovirus, aden-
ovirus, human herpes virus 6, and Epstein Barr virus), as
well as Borrelia burgdorferi, Chlamydia pneumonia, and
Mycobacterium tuberculosis. For cytokine measurement all
PE, pericardial ﬂuid (PF), and serum samples were promptly
aliquoted, transferred into chilled sterile tubes containing
a proteinase inhibitor cocktail (Complete; Roche, Penzberg,
Germany), and subsequently stored at −80◦C until analysis.
The epi- and pericardial biopsies were ﬁxed and pro-
cessed in the usual manner, embedded in paraﬃn, cut
into 4mm serial sections by microtome, and then stained
with haematoxylin-eosin for routine histology and Ziehl-
Neelson stain for mycobacteria. Pathohistology examination
was always performed by two independent experts.
For immunochemistry, biopsy samples were separately
ﬁxed and processed for identiﬁcation and characterization
of inﬁltrating cells with monoclonal antibodies, bound
immunoglobulins (IgP, IgG, IgM and IgA), and complement
ﬁxation. The following markers on inﬁltrating cells were
analyzed: CD2, CD3, CD4, CD8, CD19, CD 16, CD45Ro,
T200, CD54, CD25, CD14, and CD11c.
2.3. Immunoassay for VEGF, bFGF, IL-1β,a n dT N F - α.
The levels of cytokines have been successfully determined
in pleural and pericardial eﬀusion in previous investiga-
tions using an enzyme-linked immunosorbent assay [4, 7,
16, 21, 22]. In the present study, cytokine levels in PE
and serum were measured blinded to any clinical infor-
mation with a commercially available sandwich enzyme-
linked immunosorbent assay (ELISA) from R&D Systems
(Quantikine colorimetric sandwich ELISA, R&D Systems)
according to the manufacturer’s guidelines. In brief, after
standard procedures, for each cytokine all samples were
pipetted into the wells of the microtitre plates, speciﬁc
horseradish peroxidase-linked polyclonal antibodies were
added, and immunoreactive levels of the cytokine were
determined. The detection limit for VEGF165, bFGF, IL-1β,
and TNF-α was 9pg/mL, 3pg/mL, 1pg/mL, and 1,6pg/mL,
respectively. Both interassay and intra-assay coeﬃcients of
variation were <10% for VEGF165, bFGF, IL-1β,a n dT N F - α.
2.4.StatisticalAnalysis. Resultsaregivenasmean ±standard
deviation. Values below the detection limit were assumed
to be zero for statistical analysis. All P values < 0.05 were
considered statistically signiﬁcant. For statistical analysis
the software packages SigmaPlot version 11.0 were used.
Comparison of VEGF levels between the three groups was
performed by Kruskal-Wallis test. In case of signiﬁcant
diﬀerences between the groups, closed testing principle was
applied to compare two groups by use of the Mann-Whitney
U test. Correlation between variables was calculated using
the Spearman test.
3. Results
According to the results of pericardial eﬀusion and peri-
/epicardial biopsy samples analysis, 22 (66%) patients
had autoreactive inﬂammatory PE (12 females, 10 males,Mediators of Inﬂammation 3
Table 1: Demographic characteristics of study patients.
Variable All patients aPE vPE CAD P value∗
(n = 59) (n = 22) (n = 11) (n = 26)
Men/women 39/20 10/12 8/3 21/5# <0.05
Age (years) 66.7 ±11.46 3 .5 ±11.65 8 .7 ±11.76 8 .58 ±8.3‡ <0.05
CAD 27 (46%) 1 (5%) 0 26 (100%)#‡ <0.001
Hypertension 42 (71%) 11 (50%) 5 (45%) 26 (100%)#‡ <0.001
Diabetes mellitus 12 (20%) 2 (4%) 0 10 (38%)#‡ <0.05
Hypercholesterolemia 44 (75%) 14 (64%) 6 (55%) 24 (92%)#‡ <0.05
Creatinine (mg/dL) 1.2 ±1.24 0.88 ±0.23 1.7 ±2.51 .29 ±0.6# <0.05
Hemoglobin (g/L) 135 ± 18.77 138.86 ±15.6 124.36±22.72 137 ± 18.21 NS
Leukocytes (G/L) 8.53 ±2.81 8.62 ±3.11 9.78 ±2.99 7.61 ±1.98 NS
Protein (g/dL) 69.86 ±7.98 71.57 ±6.68‡ 63.18 ±9.11 72.06 ±6.63‡ <0.05
C-reactive protein (mg/L) 21.88 ±46.61 24.76 ±48.66 43.46 ±66.13 3.25 ±4.47 NS
Values are mean ± SD or numbers of patients (percentage).
∗Analysis of variance/chi-square or Fischer exact test.
#P<0.05 versus aPE; ‡P<0.05 versus vPE.
In 9 patients with CAD and 1 patient with aPE no biochemical data were available.







































Figure 1: VEGF levels measured in pericardial eﬀusion/pericardial ﬂuid (a) and serum (b) from patients with autoreactive pericardial
eﬀusion, viral pericardial eﬀusion, and coronary artery disease.
aPE: autoreactive pericardial eﬀusion; vPE: viral pericardial eﬀusion; CAD: coronary artery disease.
63,5±11,6 years), and 11 (33%) patients had viral inﬂam-
matory PE (3 females, 8 males, 58,7±11,7 years). For com-
parison, 26 patients with CAD (5 females, 21 males, 68,58 ±
8,3 years) were included in this investigation (Table 1).
VEGF was measurable in 10 (45%) PE and 18 (82%)
blood samples from patients with autoreactive PE and in 9
(82%) PE and 8 (73%) blood samples from patients with
viralPE.InCADpatientsVEGFwasdetectedonlyin3(12%)
PF and 4 (15%) blood samples.
Pericardial VEGF levels in autoreactive and viral pericar-
dial eﬀusion were signiﬁcantly higher compared to VEGF
in PF (P = 0,006 and P < 0,001, resp.) (Figure 1(a)).
However, pericardial VEGF levels did not diﬀer between
autoreactive and viral PE (P = 0,084). In serum, VEGF was
signiﬁcantly higher in patients with autoreactive and viral
PE compared to patients with CAD patients (P < 0,001 and
P< 0,001, resp.). As in PE, serum VEGF levels did not diﬀer
signiﬁcantly between patients with autoreactive and viral PE
(P = 0,213) (Figure 1(b)). Although statistical signiﬁcance
was not reached, pericardial VEGF levels were higher than
matched serum levels in 6 out of 22 (27%) patients with
autoreactive PE and in 6 out of 11 (55%) patients with viral
PE, (P = 0,07 for autoreactive PE; P = 0,279 for viral PE).
Basic FGF was detectable in 20 (91%) PE and 3 (14%)
serum samples from patients with autoreactive PE, 10 (91%)











































Figure 2: Basic FGF levels measured in pericardial eﬀusion/pericardial ﬂuid (a) and serum (b) from patients with autoreactive pericardial
eﬀusion, viral pericardial eﬀusion, and coronary artery disease.































Figure 3: Pericardial and corresponding serum bFGF levels in
patients with inﬂammatory pericardial eﬀusion.
viral PE, and 25 (96%) PF samples and 1 (3,8%) serum
sample from patients with CAD. Pericardial bFGF levels
were highest in patients with CAD, although statistical
signiﬁcance was only reached between CAD patients and
patients with viral PE (P = 0,006) (Figure 2(a)). In serum,
bFGF was detectable only in 3 patients with autoreactive PE,
1patientwithviralPEand1patientwithCAD(Figure 2(b)).
PericardialbFGFlevelswerehighercomparedtoserumlevels
in patients with CAD and patients with inﬂammatory PE
(Figure 3)( P ≤0,001 for CAD; P ≤0,001 for autoreactive PE;
P = 0,005 for viral PE).
IL-1β was detectable only in few PE (1 patient with viral
PE and 1 patient with CAD) and serum samples (1 patient
with viral PE). Obtained pericardial and serum levels did not
diﬀer between autoreactive PE, viral PE, and CAD.
TNF-α was detectable in PE of a smaller proportion of
patients with inﬂammatory PE (2 patients with autoreactive
Table 2: Pericardial levels of related biochemical parameters in
autoreactive and viral PE.
Variable Autoreactive PE Viral PE P value∗
LDH (U/L) 405.1 ±761.35 902.36±1008.77 0.08
Protein (g/dL) 37.05 ± 13,59 36.55 ±10.90 . 9 2
Glucose (mg/dL) 95.5 ±14.15 97.36 ±21.73 0.77
Leukocytes (G/L) 1.47 ± 3.33 1.46 ±1.24 0.15
Values are mean ± SD.
∗Analysis of variance/t-test.
In 2 patients with autoreactive PE no biochemical data were available.
PE: pericardial eﬀusion.
PE and 3 patients with viral PE) and in none of the patients
with CAD. In serum, none of the patients with inﬂammatory
PE or CAD had detectable TNF-α levels.
Relatedbiochemicalparametersandleukocytescountsin
PE from patients with autoreactive and viral PE are depicted
in Table 2. Pericardial VEGF levels correlated positively with
markers of pericardial inﬂammation (Table 3). In contrast, a
negative correlation between pericardial bFGF and markers
of pericardial inﬂammation was observed (Table 3).
4. Discussion
The present study investigated for the ﬁrst time the peri-
cardial and serum concentrations of VEGF, bFGF, IL-1β,
and TNF-α in pericardial eﬀusion and serum from patients
with inﬂammatory pericardial eﬀusion and compared them
with pericardial ﬂuid and serum levels of patients with
CAD and no history or evidence of pericardial disease.
Analysis of cytokines in pericardial eﬀusion provides a
modality to elucidate the pathophysiology of pericardial
disease and may help to identify the etiology in patients with
PE [19, 23]. However, studies related to cytokine analysis
in pericardial eﬀusion are rare. Initial investigations onMediators of Inﬂammation 5
Table 3: Correlation between VEGF and bFGF and markers of
pericardial inﬂammation in patients with inﬂammatory pericardial
eﬀusion.
Variable VEGF bFGF
LDH (U/L) in PE r 0.655 −0.542
P <0.001 0.002
Leukocytes (G/L) in PE r 0.543 −0.443
P 0.003 0.02
VEGF: vascular endothelial growth factor; bFGF: basic ﬁbroblast growth
factor; PE: pericardial eﬀusion; r,S p e a r m a nc o e ﬃcient of correlation; P: P-
value.
pericardial cytokines included only case reports [5, 6]. In
contrast, a systematic analysis of pericardial interleukin-6,
interleukin-8,andinterferon-γ investigated101patientswith
pericardial eﬀusion [4]. However, intrapericardial VEGF,
bFGF, IL-1β,a n dT N F - α levels in inﬂammatory PE have not
been studied before.
In contrast to the limited experience on cytokines in
inﬂammatory pericardial eﬀusion, numerous investigations
on cytokines in pleural eﬀusion exist. Some of the ﬁndings
could be possibly extrapolated for pericardial eﬀusion.
Pleural (and pericardial) inﬂammation is typically
accompanied by enhanced vascular permeability and both
are essential for the pathogenesis of inﬂammatory eﬀusions
leading to increased ﬂuid formation. Several studies conﬁrm
that VEGF, which has potent angiogenic, mitogenic, and
permeability-inducing properties could be implicated in the
pathogenesis of exudative pleural eﬀusions. This notion is
largely based on the ﬁndings that the levels of VEGF were
consistently higher in exudative than in transudative pleural
eﬀusions[7,16,21,24]andthatpleuralVEGFlevelscorrelate
with markers of pleural inﬂammation [16, 22]. In line
with this data, we found higher pericardial VEGF levels in
exudative, inﬂammatory PE than in PF from patients with
CAD. Moreover, VEGF levels in inﬂammatory PE correlated
positively with markers of pericardial inﬂammation (leuko-
cytes and LDH in pericardial eﬀusion).
Ar e c e n ts t u d yb yW ¨ ornle et al. also demonstrated that
viral infections lead to an increase in VEGF synthesis from
mesothelial cells [12]. According to the authors mesothelial
VEGF synthesis after activation of viral receptors could
represent the link between viral infections and formation of
pleural eﬀusion. Further studies are warranted to investigate
whether these ﬁndings also apply for viral pericardial
eﬀusion.
TheimplicationofbFGFinthepathogenesisofexudative
eﬀusions has been less extensively studied. Data from Ruiz
et al. [16] have suggested that bFGF participates in the
pathogenesis of exudative pleural eﬀusions and Strizzi et al.
[25] have demonstrated a larger contribution of bFGF in
benign than malignant eﬀusions. However, the study by Ishi-
moto et al. [26] questioned the implication of bFGF in the
formation of pleural eﬀusion. In our series, pericardial bFGF
levels were regularly elevated in patients with inﬂammatory
PE.
Inﬂammatory cells and activated endothelium can syn-
thesize and release bFGF [17, 27–29]. The inﬂammatory
reaction itself may also cause endothelial cell damage, which
results in increased bFGF production and release [30]. Basic
FGF may amplify the inﬂammatory reaction by recruiting
inﬂammatory cells [31, 32]. Furthermore, bFGF can induce
vascular permeability directly and indirectly by upregulating
VEGF [33]. However, bFGF was negatively correlated with
markers of pericardial inﬂammation (leukocytes and LDH).
One possible explanation may be that long-lasting exposure
tobFGFreducesleukocytemigrationandresponsetovarious
chemokines [31, 34, 35] after the initial ampliﬁcation of
the inﬂammatory response. Further study is required to
corroborate this ﬁnding.
In inﬂammatory pericardial eﬀusion, the presence of
cytokines within the pericardial cavity may be explained
by intrapericardial production or diﬀusion from systemic
circulation. Therefore, we compared pericardial and serum
levels of the VEGF, bFGF, IL-1β,a n dT N F - α in order to
examine whether local pericardial production is the main
source of these cytokines. We observed that pericardial
bFGF was signiﬁcantly higher compared to corresponding
serum bFGF, whereas pericardial VEGF tended to be higher
than serum levels, but the diﬀerence did not reach statistic
signiﬁcance. These ﬁndings may reﬂect preferential local
pericardialproductionofbFGF,whereasourresultsseemless
clear for VEGF. Within the pericardial cavity, cytokines are
likely to originate from multiple cellular sources. Inﬁltrating
leukocytes, activated mesothelial cells, or epicardial adipose
tissue may be involved. [17, 27, 28, 36]. The positive corre-
lation between pericardial VEGF and pericardial leukocytes
suggests that pericardial leukocytes might be one source of
VEGF. Several investigations have also shown that pleural
mesothelial cells are metabolically active and possess the
capacity to produce various cytokines [37–39]. However, so
far no study addresses the role and direct participation of
pericardialmesothelialcellsinthepathogenesisofpericardial
inﬂammation.
In addition, we observed markedly elevated bFGF levels
inPFfrompatientswithCAD.Inagreementwithourresults,
highbFGFlevelsinPFofpatientswithischemicheartdisease
have been reported before [1]. It has been suggested that
bFGF in PF may accelerate the growth of human vascular
smooth cells, induce angiogenesis, and mediate collateral
development [1, 40]. Intrapericardial administration of
bFGF promoted angiogenesis and reduced infarction size in
dogs with acute myocardial infarction [41].
IL-1β and TNF-α were detectable only in a small propor-
tion of patients with inﬂammatory PE. These results suggest
that these cytokines play a minor part in inﬂammatory PE.
In conclusion, this study provides new data regarding the
role of cytokines in the pathophysiology of inﬂammatory
pericardial eﬀusions. Elevated VEGF and bFGF levels in
inﬂammatorypericardialeﬀusionsindicatethatthesegrowth
factors might be involved in the pathogenesis of inﬂamma-
tory pericardial eﬀusions.
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